Healthcare entity
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention KRRO-110, the most common co-covered peer. Source depth averages 2 original sources per story, versus 4.1 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6 in the same window.
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention KRRO-110, the most common co-covered peer. Source depth averages 2 original sources per story, versus 4.1 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6 in the same window. OPERA appears in 1 tracked Healthcare story from March 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering OPERA. Shared-story counts are live from our verified record — not editorial picks.
Pipeline Expansion
Expected utilization of funds to advance additional candidates from the OPERA platform.
Clinical Milestone Expected
Anticipated progress updates on the KRRO-110 Phase 1/2 clinical trial for AATD.
Private Placement Announced
Korro Bio announces the closing of an $85 million oversubscribed private placement.
Korro Bio (NASDAQ: KRRO) has successfully closed an $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. The capital infusion is earmarked for the clinical advancement of its lead candidate, KRRO-110, and the expansion of its OPERA platform.
Source: manilatimes.net · Seeking Alpha
OPERA is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
